Format

Send to

Choose Destination
See comment in PubMed Commons below
Radiol Oncol. 2013 May 21;47(2):97-102. doi: 10.2478/raon-2013-0017. Print 2013 Jun.

The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma.

Author information

  • 1Department of Radiological Sciences, Nuclear Medicine Unit, University of Messina, Messina, Italy.

Abstract

BACKGROUND:

The objective of this study is to systematically review the role of positron emission tomography (PET) and PET/computed tomography (PET/CT) with Fluorine-18-Fluorodeoxyglucose (FDG) in patients with osteosarcoma (OS).

METHODS:

A comprehensive literature search of published studies through October 10(th), 2012 in PubMed/MEDLINE, Embase and Scopus databases regarding whole-body FDG-PET and FDG-PET/CT in patients with OS was performed.

RESULTS:

We identified 13 studies including 289 patients with OS. With regard to the staging and restaging of OS, the diagnostic performance of FDG-PET and PET/CT seem to be high; FDG-PET and PET/CT seem to be superior to bone scintigraphy and conventional imaging methods in detecting bone metastases; conversely, spiral CT seems to be superior to FDG-PET in detecting pulmonary metastases from OS.

CONCLUSIONS:

Metabolic imaging may provide additional information in the evaluation of OS patients. The combination of FDG-PET or FDG-PET/CT with conventional imaging methods seems to be a valuable tool in the staging and restaging of OS and may have a relevant impact on the treatment planning.

KEYWORDS:

18F-Fluorodeoxyglucose; PET/CT; bone sarcoma; osteosarcoma; positron emission tomography

PMID:
23801904
PMCID:
PMC3691088
DOI:
10.2478/raon-2013-0017
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center